证券代码：603811 证券简称：诚意药业 公告编号：2025-056 浙江诚意药业股份有限公司 控股股东之一致行动人减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | 股东名称 | 持股数量（股） | 持股比例 | 一致行动关系形成原 | | --- | --- | --- | --- | --- | | | | | | 因 | | 第一 | 颜贻意 | 77,192,080 | 23.58% | 公司的控股股东、实 | | 组 | | | | 际控制人、董事长 | | | 温州市洞头区诚 | 3,525,900 | 1.08% | 颜贻意是诚意小贷法 | | | 意小额贷款股份 | | | 定代表人及董事长， | | | 有限公司 | | | 间接持有诚意小贷 | | | | | | 27.50%股权。 | | | 颜晓玲 | 349,722 | 0.11% | 颜晓玲是颜贻意的女 | | | | | | 儿及一致行动人。 | | | 合计 | 81,067,702 | 24 ...

格隆汇9月19日丨诚意药业(603811.SH)公布，自本公告披露之日起15个交易日后的3个月内，诚意小贷 和颜晓玲拟以集中竞价交易方式或大宗交易方式合计减持所持有的以集中竞价方式取得的公司无限售条 件流通股不超过387.56万股，占公司总股本的1.18%，减持价格将按照减持实施时的市场价格确定。 ...

Group 1 - The core point of the article is that Chengyi Pharmaceutical (603811.SH) announced a plan for share reduction by its controlling shareholder and related parties, which may impact the company's stock performance [1] - The controlling shareholder Yan Yiyi and a related party plan to reduce their holdings by up to 3,875,622 shares, representing 1.18% of the total share capital [1] - The reasons for the share reduction include compliance with the regulatory requirements from the National Financial Regulatory Administration and personal funding needs [1]

每经AI快讯，9月19日，诚意药业(603811.SH)公告称，公司控股股东颜贻意的一致行动人温州市洞头区 诚意小额贷款股份有限公司和颜晓玲计划自公告披露之日起15个交易日后的3个月内，通过集中竞价交 易或大宗交易方式合计减持不超过3,875,622股，占公司总股本的1.18%。减持原因分别为根据国家金融 监管总局发布的《小额贷款公司监督管理暂行办法》规定需限期整改退出，以及个人资金需求。减持价 格将按减持实施时的市场价格确定。 ...

诚意药业（603811）(603811.SH)发布公告，自本公告披露之日起15个交易日后的3个月内，诚意小贷和 颜晓玲拟以集中竞价交易方式或大宗交易方式合计减持所持有的以集中竞价方式取得的公司无限售条件 流通股不超过387.56万股，占公司总股本的1.18%。 ...

人民财讯9月19日电，诚意药业（603811）9月19日公告，公司控股股东颜贻意持有23.58%股份，其一 致行动人诚意小贷持有公司1.08%股份，其一致行动人颜晓玲持有公司0.11%股份。诚意小贷和颜晓玲 拟以集中竞价交易方式或大宗交易方式合计减持所持有的以集中竞价方式取得的公司无限售条件流通股 不超过387.56万股，占公司总股本的1.18%。 ...

智通财经APP讯，诚意药业(603811.SH)发布公告，自本公告披露之日起15个交易日后的3个月内，诚意 小贷和颜晓玲拟以集中竞价交易方式或大宗交易方式合计减持所持有的以集中竞价方式取得的公司无限 售条件流通股不超过387.56万股，占公司总股本的1.18%。 ...

诚意药业公告，公司控股股东颜贻意的一致行动人温州市洞头区诚意小额贷款股份有限公司和颜晓玲女 士计划在2025年10月21日至2026年1月20日期间，通过集中竞价或大宗交易方式减持其持有的公司无限 售条件流通股。减持股份总数不超过387.56万股，占公司总股本的1.18%。温州市洞头区诚意小额贷款 股份有限公司计划减持不超过352.59万股，颜晓玲女士计划减持不超过34.97万股。减持价格将根据市场 价格确定。此次减持是由于监管要求和个人资金需求。 ...

Group 1: Company Performance and Strategy - The company held a half-year performance briefing on September 18, 2025, to discuss its financial results and future strategies [1] - The company's profit for the first half of 2025 increased from 27.2% in 2024 to 48.20%, driven by sustained sales growth in joint health medications and reduced losses from a previously underperforming subsidiary [2][3] - The company aims to focus on the "marine biomedicine" and "silver economy" sectors as core growth engines, leveraging opportunities from consumer upgrades and increased health awareness [2][5] Group 2: Product Development and R&D - The company has made significant progress in its health industry strategy, obtaining multiple key licenses for health food production and expanding its product offerings [2][3] - The company is advancing the development of its new drug, Eicosapentaenoic Acid Ethyl Ester soft capsules, which has received a Class 4 drug registration certificate [2][3] - The company plans to enhance its R&D efforts, with a focus on marine drugs, elderly medications, and other therapeutic areas, despite a 14.58% decrease in R&D expenses in the first half of 2025 due to payment timing [6][7] Group 3: Market Position and Competitive Advantage - The company is a leading manufacturer of glucosamine hydrochloride in China, benefiting from a comprehensive supply chain that includes both raw material and formulation production [7][8] - The company has established a competitive edge through product positioning, market presence, and cost advantages, allowing it to expand its market share across 30 provincial regions in China [7][8] - The company is committed to developing high-end niche products in marine medicine and major disease treatments, aiming for a market capitalization of 10 billion and a century-long legacy [5][6] Group 4: Future Outlook and Challenges - The company is focused on building a robust marine drug development system, integrating existing resources to expand its product line and enhance market competitiveness [3][4] - The company acknowledges the challenges in the marine medicine sector, including extraction technology and regulatory requirements, while aiming to create a differentiated product matrix [4] - The company is also adapting to the normalization of centralized procurement policies by diversifying its product range and improving quality to enhance market competitiveness [5][6]

Core Viewpoint - The company is focusing on enhancing its research and development (R&D) efforts, particularly in marine biomedicine, to drive future growth and expand its product offerings in various therapeutic areas [1][2]. Group 1: R&D and Product Development - The company plans to increase its R&D expenses for the full year 2025, despite a decrease in the first half of the year due to payment schedules for certain projects [1]. - The company has over 30 products in development, focusing on marine drugs, geriatric medications, anti-tumor drugs, traditional Chinese medicine, anti-infective drugs, digestive system treatments, and the broader health industry [1]. - The company aims to leverage its advantages in marine biomedicine to develop and industrialize marine drugs, integrating existing resources and expanding its product line with high-purity EPA and other marine-derived drugs [1]. Group 2: Market Position and Product Offerings - The company is a leading manufacturer of glucosamine hydrochloride in China, establishing a competitive advantage across the entire industry chain [2]. - The main product, glucosamine hydrochloride capsules, is available in multiple specifications (0.24g, 0.48g, 0.75g) to meet diverse patient needs [2]. - As of May 2025, the company has completed contract renewals for centralized procurement in 30 provincial regions across the country, continuously expanding its market share [2].